NCT07285811Recruiting
GLycaemic Outcomes With Whey Protein in ageING
Whey Protein Dose-response Effect on Daily Glycaemic Excursions in Very Old Individuals With Type 2 Diabetes
Source: ClinicalTrials.gov · Last updated 22 Oct 2026
Brief summary (registry, in English)
The goal of this placebo-controlled, partial crossover design study is to identify the impact of consuming whey protein before meals on free-living glucose control in older adults living with type 2 diabetes. The primary specific objective is to determine the effect of a thrice daily whey protein pre-meal supplementation at two doses, on glucose excursions over a 7-day free-living period in adults aged 70-90 years of age, living with type 2 diabetes, compared with a non-protein placebo. Participants will consume the whey protein and placebo for 7 days each, before each meal. All participants will consume the placebo and one of two doses of whey protein, in a randomised order.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- First submitted
- 18 Nov 2025
- Start date
- 2 Jan 2026
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- University of Birmingham
- Diseases
- Type 2 diabetes
- NCT number
- NCT07285811
What you commit to
- Study type: Interventional
- Planned participants: 32
- From 2 Jan 2026 to the primary completion date, 31 Mar 2027
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Currently on fast-acting insulin therapy (i.e., Humalog)
- Currently on GLP-1 therapy
Other illness
- History of gastrointestinal disease
- Recent Ischemic stroke (\<3 months).
Lab values
- Confirmed uncontrolled diabetes (HbA1C \>10% or 85mmol/mol).
Age
- \<70 years old and over 90 years of age
Other
- Habitual smoker or vaper
- Veganism
- Lactose or dairy intolerance
- Coeliac or gluten intolerance
- Experienced a hyperglycaemic or hypoglycaemic event requiring treatment in the past 12 months
- Use of anticoagulants (e.g. warfarin, rivaroxaban)
- Considered unwilling or unable to comply with the study protocol requirements by the research team
Criteria the registry did not label
- Male or female
- 70-90 years old
- Type 2 Diabetes (confirmed with glycated haemoglobin (HbA1c) \>6.5% in clinic or in SportExR)
- Stable body mass (body mass index (BMI) ≤40kg/m2)
- Generally healthy, assessed via a General Health Questionnaire (GHQ)
- Some residual beta-cell activity (confirmed with urine test on induction)
- Normal or moderately increased albuminuria (needs to be below 300mg/g)
- Normal, mildly or moderately decreased glomerular filtration rate (GFR) (needs to be above 45ml/min/1.732).
- Able and willing to attend SportExR a total of 5 times: 1 induction and 2 testing visits and 2 return check-up visits.
Age in the registry: 70 years to 90 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Heartlands Hospital Coordinator of this site? Confirm its status | Birmingham | United Kingdom | Recruiting |
| School of Sport, Exercise and Rehabilitation Sciences, University of Birmingham Coordinator of this site? Confirm its status | Birmingham | United Kingdom | Enrolling by invitation |
This page is information, not medical advice. Discuss any trial with your doctor.